This document provides a short summary of this study for a general audience. You can
find more information in the scientific summaries of the study. Links to those
summaries are provided at the end of this document.
Study names
Short Title: A study to compare five different doses of danirixin with placebo in patients
with chronic obstructive pulmonary disease.
Full Scientific Title: Randomised, double-blind, placebo-controlled, multi-centre, dose
ranging study to evaluate the efficacy and safety of danirixin tablets administered twice
daily compared with placebo for 24 weeks in adult participants with chronic obstructive
pulmonary disease.
Study Number: 205724
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When was this study done?
The study started in April 2017 and ended in October 2018.
What was the main objective of this study?
Chronic obstructive pulmonary disease (COPD) is a long-term disease of the lungs that
makes it hard to breathe and gets worse over time. Patients with COPD have inflamed
airways and/or inflammation in the lungs. This inflammation can cause shortness of
breath, coughing, and chest tightness. Reducing the severity of symptoms is important
in the treatment of COPD.
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.